Page 28 - Haematologica May 2020

M. Engelhardt et al.
18. Palumbo A, Bringhen S, Mateos MV, et al.
Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. Blood. 2015;125(13):2068-2074.
19. Kent EE, Ambs A, Mitchell SA, et al. Health- related quality of life in older adult survivors of selected cancers: data from the SEER- MHOS linkage. Cancer. 2015;121(5):758-765.
20. Facon T, Kumar S, Plesner T, et al. Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma. N Engl J Med. 2019;380(22):2104-2115.
21. Gengenbach L, Reinhardt H, Ihorst G, et al. Navigating the changing multiple myeloma treatment landscape: clinical practice pat- terns of MM patients treated in- and outside German DSMM study group trials<sup/>. Leuk Lymphoma. 2018;59(11):2692-2699.
22. Einsele H, Engelhardt M, Tapprich C, et al. Phase II study of bortezomib, cyclophos- phamide and dexamethasone as induction therapy in multiple myeloma: DSMM XI trial. Br J Haematol. 2017;179(4):586-597.
23. Köhler M, Greil C, Hudecek M, et al. Current developments in immunotherapy in the treatment of multiple myeloma. Cancer. 2018;124(10):2075-2085.
24. Kleber M, Ihorst G, Terhorst M, et al. Comorbidity as a prognostic variable in multiple myeloma: comparative evaluation of common comorbidity scores and use of a novel MM-comorbidity score. Blood Cancer J. 2011;1(9):e35.
25. Kleber M, Ihorst G, Gross B, et al. Validation of the Freiburg Comorbidity Index in 466 multiple myeloma patients and combination with the international staging system are highly predictive for outcome. Clin Lymphoma Myeloma Leuk. 2013;13(5):541- 551.
26. Kleber M, Ihorst G, Udi J, et al. Prognostic risk factor evaluation in patients with relapsed or refractory multiple myeloma receiving lenalidomide treatment: analysis of renal function by eGFR and of additional comorbidities by comorbidity appraisal. Clin Lymphoma Myeloma Leuk. 2012; 12(1):38-48.
27. Hieke S, Kleber M, König C, Engelhardt M, Schumacher M. Conditional Survival: A Useful Concept to Provide Information on How Prognosis Evolves over Time. Clin. Cancer Res. 2015;21(7):1530-1536.
28. Schumacher M, Hieke S, Ihorst G, Engelhardt M. Dynamic prediction: A chal- lenge for biostatisticians, but greatly needed by patients, physicians and the public. Biom J. 2019 Mar 25. [Epub ahead of print]
29. Caers J, Garderet L, Kortüm KM, et al. European Myeloma Network recommenda-
tions on tools for the diagnosis and monitor- ing of multiple myeloma: what to use and when. Haematologica. 2018;103(11):1772- 1784.
potential biomarkers of aging? J Geriatr
Oncol. 2014;5(2):204-218.
40. Engelhardt M, Selder R, Pandurevic M, et al.
[Multidisciplinary Tumor Boards: Facts and Satisfaction Analysis of an Indispensable Comprehensive Cancer Center Instrument]. Dtsch Med Wochenschr. 2017;142(9):e51-
30. Kleber M, Ihorst G, Deschler B, et al.
Detection of renal impairment as one specific comorbidity factor in multiple myeloma:
multicenter study in 198 consecutive e60.
patients. Eur J Haematol. 2009;83(6):519-527. 31. Corre J, Munshi N, Avet-Loiseau H. Genetics of multiple myeloma: another het- erogeneity level? Blood. 2015;125(12):1870-
1876.
32. Moreau P, Cavo M, Sonneveld P, et al.
Combination of international scoring sys- tem 3, high lactate dehydrogenase, and t(4;14) and/or del(17p) identifies patients with multiple myeloma (MM) treated with front-line autologous stem-cell transplanta- tion at high risk of early MM progression- related death. J Clin Oncol. 2014;32(20): 2173-2180.
33. Neben K, Jauch A, Bertsch U, et al. Combining information regarding chromo- somal aberrations t(4;14) and del(17p13) with the International Staging System classi- fication allows stratification of myeloma patients undergoing autologous stem cell transplantation. Haematologica. 2010;95(7):1150-1157.
41. Soto-Perez-de-Celis E, Li D, Yuan Y, Lau YM, Hurria A. Functional versus chronolog- ical age: geriatric assessments to guide deci- sion making in older patients with cancer. Lancet Oncol. 2018;19(6):e305-e316.
42. Abel GA, Klepin HD. Frailty and the man- agement of hematologic malignancies. Blood. 2018;131(5):515-524.
43. Engelhardt M, Mertelsmann R, Duyster J. Das Blaue Buch. Springer; 2020.
44. Waldschmidt JM, Keller A, Ihorst G, et al. Safety and efficacy of vorinostat, borte- zomib, doxorubicin and dexamethasone in a phase I/II study for relapsed or refractory multiple myeloma (VERUMM study: vorinostat in elderly, relapsed and unfit mul- tiple myeloma). Haematologica. 2018;103(10):e473-e479.
45. Greil C, Engelhardt M, Ihorst G, et al. Allogeneic transplantation of multiple myeloma patients may allow long-term survival in carefully selected patients with acceptable toxicity and preserved quality of life. Haematologica. 2019;104(2):370-
34. Palumbo A, Avet-Loiseau H, Oliva S, et al.
Revised International Staging System for
Multiple Myeloma: A Report From 379.
International Myeloma Working Group. J
Clin Oncol. 2015;33(26):2863-2869.
35. Avet-Loiseau H, Durie BGM, Cavo M, et al. Combining fluorescent in situ hybridization data with ISS staging improves risk assess- ment in myeloma: an International Myeloma Working Group collaborative
project. Leukemia. 2013;27(3):711-717.
36. Binder M, Rajkumar SV, Ketterling RP, et al. Substratification of patients with newly diagnosed standard-risk multiple myeloma.
Br J Haematol. 2019;185(2):254-260.
37. Milani P, Vincent Rajkumar S, Merlini G, et al. N-terminal fragment of the type-B natri- uretic peptide (NT-proBNP) contributes to a simple new frailty score in patients with newly diagnosed multiple myeloma. Am J
Hematol. 2016;91(11):1129-1134.
38. Cook G, Royle K-L, Pawlyn C, et al. A clini- cal prediction model for outcome and thera- py delivery in transplant-ineligible patients with myeloma (UK Myeloma Research Alliance Risk Profile): a development and validation study. Lancet Haematol.
2019;6(3):e154-e166.
39. Pallis AG, Hatse S, Brouwers B, et al.
Evaluating the physiological reserves of older patients with cancer: the value of
46. Küchlin S, Duffner J, Scheubeck S, et al. Kidney embolization induces prompt organ response in a 86-year-old patient with MGRS-related AL-amyloidosis. Hemodial Int. 2019;23(2):E59-E64.
47. Facon T, Dimopoulos MA, Meuleman N, et al. A simplified frailty scale predicts out- comes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial. Leukemia. 2020;34(1):224-233.
48. Engelhardt M, Dold SM, Ihorst G, Knaus J, Schumacher M. R-MCI webpage. 2015.
49. Kumar SK, Dispenzieri A, Lacy MQ, et al.
Continued improvement in survival in mul- tiple myeloma: changes in early mortality and outcomes in older patients. Leukemia. 2014;28(5):1122-1128.
50. Campisi J, Kapahi P, Lithgow GJ, et al. From discoveries in ageing research to therapeu- tics for healthy ageing. Nature. 2019;571 (7764):183-192.
51. Mina R, Bringhen S, Wildes TM, Zweegman S, Rosko AE. Approach to the Older Adult With Multiple Myeloma. ASCO Educational Book 2019; vol 39. doi.org/10.1200/EDBK_239067.Am Soc Clin Oncol Educ Book. 2019;39:500-518.
1188
haematologica | 2020; 105(5)